Beijing, China, November 25, 2025 – Gan & Lee Pharmaceuticals. (hereinafter "Gan & Lee" stock code: 603087.SH), today announced that it has entered into an exclusive license and supply agreement with Productos Científicos S.A. de C.V. (hereinafter "PC") also known as CARNOT^® Laboratorios , headquartered in Mexico and a leading pharmaceutical company in Latin America, for its self-developed biweekly GLP-1 receptor agonist, Bofanglutide (Development code: GZR18).

Under the terms of the agreement, Gan & Lee grants PC an exclusive license to develop and commercialize Bofanglutide injection in Latin American countries, including Mexico, Brazil and other major countries. This initiates the new Latin American commercialization footprint for its innovative drug Bofanglutide.

Significant Potential of Biweekly Formulation for Weight Loss and Compliance

Bofanglutide injection is a core, self-developed biweekly GLP-1 RA from Gan & Lee, targeting treatment for adults with type 2 diabetes and weight management in overweight or obese individuals. As a potential first-in-class global Biweekly GLP-1 RA, Bofanglutide demonstrates via clinical data that it achieves weight loss outcomes comparable to or exceeding those of currently marketed GLP-1 RA products, with safety and tolerability consistent with the GLP-1 RA class, effectively lowering both blood glucose and body weight.

Leveraging its potential in glycemic and weight management, Bofanglutide has progressed rapidly in domestic and international clinical trials. In 2024, Phase 3 clinical trials for weight loss were initiated, along with a head-to-head clinical trial comparing Bofanglutide with Novo Nordisk's Ozempic^® . Additionally, another head-to-head Phase 3 clinical trial comparing Bofanglutide with Novo Nordisk's Wegovy^® was initiated in 2025. The U.S. clinical development is progressing in parallel. A head-to-head Phase 2 clinical trial comparing Bofanglutide with Tirzepatide (Zepbound^®) completed full patient enrollment in H1 2025 and is expected to be completed in H1 2026.

Expanding the Latin American Market: New Opportunities for GLP-1 RA Therapy

In 2024, the Latin American GLP-1 RA market generated USD 1.323 billion in revenue. From 2025 to 2030, the market is expected to grow at a CAGR of 16.8%, reaching approximately USD 3.4 billion by 2030.¹

Through this collaboration with PC, PC will conduct dedicated clinical trials in Brazil, Mexico, and Colombia to generate the robust clinical data needed for regulatory filings of Bofanglutide injection in Latin America. Bofanglutide is positioned to become the first commercially available biweekly GLP-1 RA in the region. Compared with existing weekly formulations, biweekly dosing regimen reduces the number of annual injections by 50%. This reduction is expected to significantly improve treatment adherence and accessibility for patients with diabetes and overweight/obesity.

Gan & Lee Chief Commercial Officer Kai Du and Key Accounts Director, Dr Dhaval Soneji commented and believes: "This strategic partnership with PC marks a new phase in our expansion in Latin America. Beyond strengthening our localized presence in the region, this collaboration initiates the first international deployment of our self-developed innovative drugs, paving the way for bringing clinically valuable original pharmaceutical products to overseas markets. As a company committed to long-term global expansion, Gan & Lee has consistently adhered to its dual strategy of 'Innovation + Globalization'. Notably, this milestone partnership not only validates the value of our years of sustained investment in research and development (R&D) but also lays a solid foundation for the subsequent global rollout of our broader pipeline products."

PC's Chairman, Guy Jean Savoir, and CEO, Edmundo Jimenez, added:This collaboration with Gan & Lee represents an important advancement for metabolic disease management in Latin America. Through this partnership, we aim to accelerate regulatory pathways for Bofanglutide so that it can meaningfully impact public-health outcomes in a region facing a rapidly growing burden of diabetes and obesity. We look forward to working closely with Gan & Lee to advance this important molecule for the benefit of patients, healthcare providers, and the broader health systems of Latin America."

Reference:

1. Grand View Horizon.(2025). Latin America GLP-1 Receptor Agonist  Market  Size & Outlook,2025-2030.  https://www.grandviewresearch.com/horizon/outlook/glp-1-receptor-agonist-mark et/latin-america

About Productos Científicos S.A. de C.V.
Productos Científicos S.A. de C.V. , a Mexico headquartered company also known as Carnot^® Laboratorios is focused in R&D, manufacturing and Distribution of Pharmaceutical products with 80+ years of presence in the Mexico and Latin American Region.

With over 1500 employees and with Presence across the Region has been expanding the reach in the therapeutic areas of Respiratory, Dermatology, Gastroenterology, Cardio metabolic, pediatrics, CNS, women health, Biopharmaceuticals and Vaccines.

Carnot^® ranks among Regional players, in Top 5 by Value as per the data published by IQVIA in Mexico with No.1 position in gastroenterology and growing very fast in the Latin American Region.

About Gan & Lee

Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin^®), fast-acting lispro injection (Prandilin™), fast-acting aspart injection (Rapilin^®), mixed protamine zinc lispro injection (25R) (Prandilin™25), aspart 30 injection (Rapilin^®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin^®30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine^®).

In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked  first among all selected companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine^®) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee’s competitiveness in both international and domestic markets.

In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.